{
    "nctId": "NCT03270007",
    "briefTitle": "Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy",
    "officialTitle": "Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Primary Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 304,
    "primaryOutcomeMeasure": "distant disease-free survival (DDFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients, 18\u2266age \u226666 years\n* Biopsy proven lymph node positive, estrogen receptor\\<10%\u3001progesterone receptor \\<10% and human epidermal growth factor receptor-2 negative primary breast cancer\n* Must have completed neo-adjuvant chemotherapy with a standard regimen(containing both anthracycline and paclitaxel)\n* Must have undergone surgery to remove the primary tumor by either a mastectomy or enlarged local excision\n* Postoperative residual positive lymph nodes\n* Adequate recovery from recent surgery\n* No history of other malignancies\n* No currently uncontrolled diseased or active infection\n* Not pregnant or breast feeding, and on appropriate birth control if of child-bearing potential\n* Adequate cardiovascular function reserve with a myocardial infarction within the past six month\n* without radiotherapy and chemotherapy contraindication\n* Adequate hematologic function with:\n\n  1. Absolute neutrophil count (ANC) \u22651500/mm3\n  2. Platelets \u2265100,000/ mm3\n  3. Hemoglobin \u226510 g/dL\n* Adequate hepatic and renal function with:\n\n  1. Serum bilirubin \u22641.5\u00d7UNL\n  2. Alkaline phosphatase and alanine aminotransferase (ALT) \u22642.5 x ULN. (\u22645 x ULN is acceptable in the setting of hepatic metastasis)\n  3. BUN between 1.7 and 8.3 mmol/L\n  4. Cr between 40 and 110 umol/L\n* Knowledge of the investigational nature of the study and Ability to give informed consent\n* Ability and willingness to comply with study procedures.\n\nExclusion Criteria:\n\n* Known or suspected distant metastases\n* Concurrent malignancy or history of other malignancy\n* Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months, arrhythmia, unstable diabetes, hypercalcemia) or active infection\n* Geographical, social, or psychological problems that would compromise study compliance\n* Known or suspected hypersensitivity to vinorelbine",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}